Cardiovascular Risk and Mineral Bone Disorder in Patients with Chronic Kidney Disease

• Main Authors: Hagen Staude (Author), Susann Jeske (Author), Karin Schmitz (Author), Gert Warncke (Author), Dagmar-Christiane Fischer (Author)
• Format: Book
• Published: Karger Publishers, 2013-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1420-4096; 1423-0143; 10.1159/000343402
• Keywords: Calcification; Calcitriol; Cardiovascular risk; Chronic kidney disease-mineral bone disorder (CKD-MBD); Fetuin-A; Fibroblast growth factor-23 (FGF-23); Klotho; Parthyroid hormone; Dermatology; RL1-803; Diseases of the circulatory (Cardiovascular) system; RC666-701; Diseases of the genitourinary system. Urology; RC870-923
• Source: Kidney & Blood Pressure Research, Vol 37, Iss 1, Pp 68-83 (2013)

The term chronic kidney disease-mineral bone disorder has been coined recently to highlight that the disturbed mineral and bone metabolism is a major contributor to vascular calcification and finally cardiovascular disease. This syndrome is characterized by clinical, biochemical and/or histological findings, i.e. i) biochemical alterations in the homeostasis of calcium, phosphate and their key player parathyroid hormone (PTH), Fibroblast growth factor-23 (FGF-23), klotho and vitamin-D, ii) the occurrence of vascular and/or soft tissue calcification, and iii) an abnormal bone structure and/or turnover. Apart from the combined and synergistic action of "traditional" and uremia-related risk factors, promoters and inhibitors of calcification have to be considered as well. This review will focus on the disturbed mineral metabolism as the triggering force behind distortion of vascular integrity and cardiovascular malfunction in CKD patients.